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Abstract: BACKGROUND With recent advances in technology, patients with acute respiratory distress
syndrome (ARDS) and severe acute exacerbations of chronic obstructive pulmonary disease (ae-COPD)
could benefit from extracorporeal CO2 removal (ECCO2R). However, current evidence in these indications
is limited. A European ECCO2R Expert Round Table Meeting was convened to further explore the
potential for this treatment approach. METHODS A modified Delphi-based method was used to collate
European experts’ views to better understand how ECCO2R therapy is applied, identify how patients are
selected and how treatment decisions are made, as well as to identify any points of consensus. RESULTS
Fourteen participants were selected based on known clinical expertise in critical care and in providing
respiratory support with ECCO2R or extracorporeal membrane oxygenation. ARDS was considered
the primary indication for ECCO2R therapy (n = 7), while 3 participants considered ae-COPD the
primary indication. The group agreed that the primary treatment goal of ECCO2R therapy in patients
with ARDS was to apply ultra-protective lung ventilation via managing CO2 levels. Driving pressure
(฀ 14 cmH2O) followed by plateau pressure (Pplat; ฀ 25 cmH2O) was considered the most important
criteria for ECCO2R initiation. Key treatment targets for patients with ARDS undergoing ECCO2R
included pH (> 7.30), respiratory rate (< 25 or < 20 breaths/min), driving pressure (< 14 cmH2O)
and Pplat (< 25 cmH2O). In ae-COPD, there was consensus that, in patients at risk of non-invasive
ventilation (NIV) failure, no decrease in PaCO2 and no decrease in respiratory rate were key criteria for
initiating ECCO2R therapy. Key treatment targets in ae-COPD were patient comfort, pH (> 7.30-7.35),
respiratory rate (< 20-25 breaths/min), decrease of PaCO2 (by 10-20%), weaning from NIV, decrease
in HCO3− and maintaining haemodynamic stability. Consensus was reached on weaning protocols for
both indications. Anticoagulation with intravenous unfractionated heparin was the strategy preferred by
the group. CONCLUSIONS Insights from this group of experienced physicians suggest that ECCO2R
therapy may be an effective supportive treatment for adults with ARDS or ae-COPD. Further evidence
from randomised clinical trials and/or high-quality prospective studies is needed to better guide decision
making.
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Abstract
Background: With recent advances in technology, patients with acute respiratory distress syndrome (ARDS) and
severe acute exacerbations of chronic obstructive pulmonary disease (ae-COPD) could benefit from extracorporeal
CO2 removal (ECCO2R). However, current evidence in these indications is limited. A European ECCO2R Expert Round
Table Meeting was convened to further explore the potential for this treatment approach.
Methods: A modified Delphi-based method was used to collate European experts’ views to better understand how
ECCO2R therapy is applied, identify how patients are selected and how treatment decisions are made, as well as to
identify any points of consensus.
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Results: Fourteen participants were selected based on known clinical expertise in critical care and in providing
respiratory support with ECCO2R or extracorporeal membrane oxygenation. ARDS was considered the primary
indication for ECCO2R therapy (n = 7), while 3 participants considered ae-COPD the primary indication. The group
agreed that the primary treatment goal of ECCO2R therapy in patients with ARDS was to apply ultra-protective lung
ventilation via managing CO2 levels. Driving pressure (≥ 14 cmH2O) followed by plateau pressure (Pplat;
≥ 25 cmH2O) was considered the most important criteria for ECCO2R initiation. Key treatment targets for patients
with ARDS undergoing ECCO2R included pH (> 7.30), respiratory rate (< 25 or < 20 breaths/min), driving pressure (<
14 cmH2O) and Pplat (< 25 cmH2O). In ae-COPD, there was consensus that, in patients at risk of non-invasive
ventilation (NIV) failure, no decrease in PaCO2 and no decrease in respiratory rate were key criteria for initiating
ECCO2R therapy. Key treatment targets in ae-COPD were patient comfort, pH (> 7.30–7.35), respiratory rate (< 20–25
breaths/min), decrease of PaCO2 (by 10–20%), weaning from NIV, decrease in HCO3
− and maintaining
haemodynamic stability. Consensus was reached on weaning protocols for both indications. Anticoagulation with
intravenous unfractionated heparin was the strategy preferred by the group.
Conclusions: Insights from this group of experienced physicians suggest that ECCO2R therapy may be an effective
supportive treatment for adults with ARDS or ae-COPD. Further evidence from randomised clinical trials and/or
high-quality prospective studies is needed to better guide decision making.
Keywords: Acute respiratory distress syndrome, Chronic obstructive pulmonary disease, CO2 removal, Consensus,
Driving pressure, ECCO2R, Gas exchange, Lung protective ventilation, Tidal volume, Therapy experience
Background
Advances in technology to deliver extracorporeal car-
bon dioxide removal (ECCO2R) therapy have simpli-
fied this approach, making it easier to deploy for the
management of adults with both hypoxaemic and
hypercapnic acute respiratory failure (ARF) [1–4]. In
patients with acute respiratory distress syndrome
(ARDS), ECCO2R therapy may be used to allow ultra-
protective lung ventilation (UPLV) and reduce
ventilator-induced lung injury (VILI) by decreasing
tidal volume (VT), both plateau (Pplat) and driving
pressures and respiratory rate, while also controlling
respiratory acidosis [5–14]. In patients with acute ex-
acerbations of chronic obstructive pulmonary disease
(ae-COPD) with severe respiratory acidosis and hyper-
capnic respiratory failure, ECCO2R therapy may be
applied to prevent intubation in patients at risk of
non-invasive ventilation (NIV) failure [15]. It may also
be used to hasten weaning from mechanical ventilation
(MV) and early extubation in those who require inva-
sive ventilation [10, 15–17].
However, there is currently limited evidence regarding
the use of ECCO2R therapy in these indications, with
available data limited to the description of single cases
or to case series that include a small number of patients
[16, 18–21], as well as a few retrospective matched
cohort studies [15, 22]. Additionally, questions remain
on how best to implement a therapy that might be
associated with serious side-effects [1]. Ongoing and
published trials such as VENT-AVOID (NCT03255057),
REST (NCT02654327) [2] and SUPERNOVA (NCT0228
2657) [11, 12, 23] are expected to provide valuable
evidence to support decision making.
Given the potential of ECCO2R therapy to provide
effective supportive treatment for a wide range of patient
groups, we convened a European ECCO2R therapy
Expert Round Table Meeting to better understand how
ECCO2R therapy is applied in key diagnostic groups, e.g.
patients with ARDS or ae-COPD, identify how patients
are selected, understand how treatment decisions are
made and delineate areas of consensus in the group.
Methods
Research questions and objectives
The ECCO2R therapy Expert Round Table Meeting was
held in Brussels in July 2019 and was attended by 14
clinicians who regularly provide ECCO2R therapy in
hospitals across Europe in order to provide a European
perspective on ECCO2R therapy. Each attendee was a
senior clinician/intensivist invited based on their experi-
ence delivering ECCO2R therapy, with and without
continuous renal replacement therapy, using different
devices. The attendees had direct clinical experience
with a wide range of ECCO2R devices, including ALung,
iLA, Prismalung and PALP (the later had been removed
from the market at the time of the meeting due to loss
of the distribution agreement). In addition, several of the
attendees are principal investigators in recently com-
pleted or ongoing clinical trials, including randomised
controlled trials such as REST and SUPERNOVA.
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Conflict of interest declarations for the attendees can be
found at the end of the manuscript.
The meeting objectives were to better define and
understand the application of ECCO2R therapy in key
indications (ARDS and ae-COPD), to identify patient
selection criteria and when to initiate and stop/wean
patients from treatment and to determine points of
consensus and differences in clinical practice in those
centres represented at the meeting. A non-systematic
search of MEDLINE, ClinicalTrials.gov and other sites
was performed to identify key studies and trials to sup-
port the development of the questions and the content
of the meeting.
Data collection and analysis
A modified Delphi-based method (Fig. 1) was used to
collate the clinicians’ views in three rounds of question-
ing [24]. The meeting questions as well as the pre-
meeting and post-meeting questionnaires were
developed by JG and KH before being reviewed and
approved by AC. JG and KH were present as Baxter
employees and moderators, but were not permitted to
provide answers or responses, either to the survey ques-
tions or during the meeting. Round 1 data were
collected via an interactive PDF questionnaire circulated
in advance of the meeting, and results were analysed an-
onymously. Round 2 data were collected during the
meeting, attendees were divided into 4 subgroups and
the questions were presented by an independent facilita-
tor. Open questions were used to encourage freedom of
response, and the meeting was designed to allow the
attendees adequate time to consider and respond to the
questions based on their experience. Attendees could
respond to the questions either through anonymous
electronic voting or by inputting responses into a micro-
computer, with responses collected and discussed openly
by the group. Round 3 was a second interactive PDF
questionnaire, circulated post-meeting, designed to fol-
low up on discussion points raised at the face-to-face
meeting, with results analysed anonymously. Details on
the process for information gathering and the questions
are provided in Additional file 1.
Target values for ventilation parameters of interest—
criteria for initiation of ECCO2R therapy and treatment
targets for ECCO2R therapy in both ARDS and ae-
COPD—were collected during the three rounds of
questioning. These values were subsequently evaluated
for consensus. To facilitate the analysis of the responses
for certain questions, a scoring system was employed.
Participants were asked to score their responses in order
of importance, giving them a score (e.g. from 1 to 8, de-
pending on the number of variables). Scores were then
combined to give a total score for each parameter, with
higher scores indicating a higher perceived importance.
To determine whether a consensus was reached or not
based on participant responses to the questions, a
threshold of ≥ 80% of participants in agreement was used
to define if consensus was reached, a level that has been
used in previous analyses [25]. Majority agreement
indicates that ≥ 50% of participants agreed, but consen-
sus level was not reached, and no agreement means that
< 50% of participants agreed. The report was drafted by
an independent medical writing company (SciMentum,
Nucleus Global) and paid for by Baxter in line with
Good Publication Practice 3. The various drafts were
reviewed and approved by AC before being reviewed by
the full author team. All authors provided their approval
to submit and meet the ICMJE criteria for authorship.
Results
Attendee clinical experience
Twelve clinicians completed the pre-meeting survey:
eight worked in Combined Surgical and Medical inten-
sive care units (ICUs), while the others were employed
Fig. 1 Overview of the five-step Delphi method used in the Round Table Meeting. Each step was a distinct process that was completed before
the following step was initiated. Results and discussions from each step were independently analysed and used to inform the direction and
content of the following steps, e.g. if the group were split on a topic, then clarifying questions were crafted to guide the discussions in the
following step(s) to identify and explore points of consensus or difference. GPP3, Good Publication Practice 3
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in Medical ICUs (n = 2), Surgical ICUs (n = 2) and
Cardiac Surgery ICUs (n = 2); respondents could be
employed at more than one type of centre. ICUs had a
median of 20 beds/unit and 400–2000 admissions/year.
Extracorporeal membrane oxygenation (ECMO) experi-
ence of participants ranged from 0 to 80 veno-venous
ECMO procedures/year and 0 to 220 veno-arterial
ECMO procedures/year.
Indications and rationale for ECCO2R based on pre-
meeting survey
Analysis of the Round 1 pre-meeting survey responses
revealed that ARDS was considered the primary indica-
tion for ECCO2R therapy by 7 participants, while 3
participants considered ae-COPD to be the primary indi-
cation. Severe asthma was also mentioned as another
potential ECCO2R indication, although less frequently.
The median number of ARDS admissions (as per the
Berlin definition [26]) was 60 patients per centre per
year, with some centres admitting up to 500 patients per
year. While the most common criteria stated in the pre-
meeting responses for initiating ECCO2R therapy in
patients with ARDS were to manage hypercapnia with
acidosis, although specific criteria varied across the
ICUs, likewise, weaning criteria shared at Round 1 varied
significantly, with no clearly consistent management
pattern being identified between centres. However, most
participants (92%) indicated that they would place
patients with ARDS in the prone position when using
ECCO2R therapy. The number of ae-COPD admissions
ranged from 0 to 250 patients per centre per year
(median 50). Participants indicated that ECCO2R
therapy was predominantly initiated to prevent intub-
ation in patients at risk of NIV failure or to facilitate
extubation in patients who had been intubated after NIV
failure.
Use of ECCO2R therapy in patients with ARDS
During the Expert Round Table Meeting and post-
meeting survey (Rounds 2 and 3, respectively), the group
considered the ventilation parameters for implementa-
tion of a lung protective ventilation (LPV) strategy in all
patients with ARDS and agreed upon the following
targets: driving pressure, 10–14 cmH2O; positive end-
expiratory pressure (PEEP), 10–14 cmH2O; Pplat, 25–
29 cmH2O; and respiratory rate either 20–25 or 25–30
breaths/min, although most of the group would target a
respiratory rate of 25 breaths/min. There was some vari-
ation in responses among the group when asked about
target pH, with half of participants opting for a target
pH value of 7.25–7.30, while others indicated the target
should be > 7.30 (n = 4), < 7.25–7.30 (n = 2) or < 7.20
(n = 1). Finally, the panellists thought VT should be set
at 6.0 mL/kg of predicted body weight (PBW), although
6.1–7.0 or 7.1–8.0 mL/kg PBW were also considered to
be reasonable targets. When asked in the post-meeting
survey (Round 3) about the preferred ventilation mode
used for patients with ARDS undergoing LPV, the group
were split with respect to pressure control (pressure
assist) (n = 8) and flow control (volume assist) (n = 6)
modes of ventilation. These recommendations agreed
with the most recent guidelines for the ventilation man-
agement of patients with ARDS [27, 28].
There was consensus among the group (91% [2
participants were unavailable for this question, 11 of
n = 12/14 voted in favour]) that the primary
treatment goal of ECCO2R therapy for patients with
ARDS was to apply UPLV via managing CO2 levels.
For initiating ECCO2R therapy in patients with ARDS,
driving pressure (≥ 14 cmH2O) followed by Pplat (≥
25 cmH2O) was considered the most important
criteria, and this was confirmed in the post-meeting
survey (Tables 1 and 2). Additional key parameters
included pH (< 7.25), reducing VT to < 6 mL/kg PBW,
PaCO2 (> 60–80 mmHg), respiratory rate (≥ 25 to >
30 breaths/min), PaO2/FiO2 (100–200) and PEEP
(combined findings from Rounds 2 and 3).
Participants were evenly split during the meeting on
the primary rationale for ECCO2R therapy, being rescue
therapy in patients with ARDS undergoing injurious
MV, i.e. those with very high plateau and driving
pressures despite reduced VT and PEEP (n = 7), or to
facilitate UPLV to prevent the deleterious effects of MV
in patients already undergoing LPV (n = 7). Based on the
results of the post-meeting survey, a consensus was
reached among the group (12/14, 86% of participants)
that ECCO2R was a strategy they would consider select-
ing for rescue in patients with ARDS. Typical character-
istics for initiating ECCO2R in a rescue situation
obtained as part of the post-meeting survey are
summarised in Table 2. A majority (10/14, 71% of
participants) indicated that they would select ECCO2R
as a means of facilitating UPLV for patients with ARDS,
and typical characteristics for selecting patients are
summarised in Table 2.
For both potential indications, patients would not be
considered suitable for an ECCO2R strategy if they met
the indications for ECMO, such as severe or refractory
ARDS [29] and presence of severe right heart failure
(ECMO may be a more adequate treatment for these pa-
tients), in cases where anticoagulation is contraindicated
and for those with major comorbidities and/or predicted
survival of < 1 year.
The group considered treatment targets for their
patients with ARDS undergoing ECCO2R. A consensus
was reached regarding driving pressure (< 14 cmH2O)
and respiratory rate (< 25 or < 20 breaths/min). There
was majority agreement with respect to targets for Pplat
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(< 25 cmH2O), pH (> 7.30 [Rounds 2 and 3]), PaCO2 (<
50 or < 55 mmHg) and VT (≤ 6mL/kg PBW). Other tar-
get parameters were not proposed by the group
(Table 1). The expected average length of time patients
with ARDS would remain on ECCO2R therapy was sug-
gested to be 1–3 days (n = 5) and 4–6 days (n = 9).
Following discussion during the meeting on a
protocol for weaning from ECCO2R in patients with
ARDS, a protocol was proposed and reviewed as part
of the post-meeting survey (Table 3). The group
voted on each step and reached consensus (92% of
participants, n = 13) that this proposal was a suitable
weaning strategy.
Use of ECCO2R therapy in patients with ae-COPD
There was consensus during the meeting that patients
with ae-COPD who should receive ECCO2R therapy
were those at risk of NIV failure, as well as patients re-
cently initiated on MV after NIV failure to allow for
early extubation within 24 h of initiating ECCO2R
therapy. Other patient groups would be considered (e.g.
patients on prolonged MV who require weaning from
invasive ventilation and patients who are refusing intub-
ation), but a consensus was not reached.
The group agreed that for patients with ae-COPD at
risk of NIV failure, ‘no decrease in PaCO2’ and ‘no
Table 1 ECCO2R treatment criteria for patients with ARDS
Parameter Target Score
Initiation criteria
Driving pressure ≥ 14 cmH2O 31 Consensus
Pplat ≥ 25 cmH2O 22 Consensus
PaCO2 > 60–80mmHg 21 Majority agreement
pH < 7.25 20 Majority agreement
Reduce VT to < 6mL/PBW – 18 Majority agreement
Respiratory rate ≥ 25 to > 30 14 Majority agreement
PaO2/FiO2 100–200 10 Majority agreement
PEEP – 8 No agreement
Treatment targets
Driving pressure < 14 cmH2O 66* Consensus
Pplat < 25 cmH2O 57* Majority agreement
†
Respiratory rate < 25 or < 20 breaths/min 44* Consensus
pH > 7.30 39* Majority agreement
VT ≤6 mL/PBW 39* Majority agreement
PaCO2 < 50–55mmHg 30 Majority agreement
Criteria for ECCO2R treatment considered to be of importance and selected from the provided list. Target describes any potential target values identified, with ‘–’
indicating that no target parameter was provided or considered relevant. Score indicates the combined total score, with higher scores indicating a higher
perceived importance. Consensus means a consensus threshold (≥ 80%) was reached, majority agreement means ≥ 50% agreed but consensus level was not
reached, and no agreement means < 50% agreed
*Based on the post-meeting survey. †Note, for Pplat, a consensus threshold of 80% was not reached in the meeting; in the post-meeting survey, it was rated as the
second most important target
Table 2 Typical characteristics for initiating ECCO2R for rescue
therapy and to facilitate ultra-protective ventilation in ARDS
Parameter Target for initiation in:
Rescue
Target for initiation in:
Ultra-protective ventilation
Driving pressure > 15 to 20 cmH2O > 13 to 15 cmH2O
Pplat > 30 to 35 cmH2O ≥ 25 cmH2O
PaCO2 ≥ 60 mmHg ≥ 60 mmHg
pH < 7.25–7.30 < 7.25–7.30
Respiratory rate > 20 to 30 breaths/min > 20 breaths/min
PaO2/FiO2 < 150 < 150
PEEP > 8 to 15 ≥ 8
Responses were captured during the post-meeting survey (Round 3) and
general themes were identified
Table 3 ECCO2R weaning protocol for patients with ARDS
Weaning criteria and steps for weaning for ECCO2R in ARDS*
ECCO2R will be applied for at least 48 h
PaO2/FiO2 > 200mmHg before testing weaning possibility
Set VT at 6 mL/PBW and PEEP 5–10 cmH2O
Driving pressure should be < 14 cmH2O
Respiratory rate should be 20–30 breaths/min
Reduce gas flow to zero, using 2 L/min decremental steps
While weaning, pH should remain > 7.30 and respiratory rate < 25
breaths/min
Patient will be weaned off ECCO2R therapy after a minimum of 12 h of
stability under these settings (including pH > 7.30 and respiratory rate <
25 breaths/min)
*A consensus was reached for all of these criteria and steps
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decrease in respiratory rate’ while on NIV were both key
initiation criteria for ECCO2R therapy (Table 4). These
criteria were considered indicative of NIV failure.
Clinical signs of respiratory failure and pH (< 7.25 [n =
5] or 7.25–7.30 [n = 6]) would be considered as initiation
criteria by most of the participants. Baseline PaCO2 and
respiratory rate as main triggers were favoured by less
than half of participants. For patients with ae-COPD
who had already been intubated, criteria for initiating
ECCO2R therapy varied (Table 4).
Factors for excluding patients with ae-COPD from
ECCO2R typically included patients with end-stage
disease (the group highlighted that markers for this in-
clude severe functional limitation and cachexia); contra-
indications to anticoagulation; problems with vascular
access; patient’s wishes, e.g. refusal to be intubated, ex-
cept in cases where ECCO2R therapy represented the
last resource accepted by the patient; poor quality of life;
and the patient not being a candidate for MV.
Treatment targets for patients with ae-COPD receiving
ECCO2R therapy were, in order of perceived importance
(Table 5), comfortable patient, pH (> 7.35/7.30; no
consensus on specific pH), respiratory rate (< 20–25
breaths/min), decrease of PaCO2 by 10–20%, weaning
from NIV, decrease in HCO3
− and maintaining haemo-
dynamic stability. Consensus on a weaning protocol for
patients with ae-COPD was reached during the meeting
(Table 5).
Anticoagulation strategy for patients receiving ECCO2R
Responses obtained during Round 1 (pre-meeting sur-
vey) showed that heparin was the preferred choice of
anticoagulant used during ECCO2R therapy (~ 80% of
participants stated that heparin was their anticoagulant
of choice). This was confirmed in the post-meeting
survey, in which unfractionated heparin was the
anticoagulant of choice for the majority (~ 90% of partic-
ipants). The proposed heparin anticoagulation protocol
agreed by the group is shown in Table 6. Lastly, argatro-
ban was the group’s preferred anticoagulant in case of
proven heparin-induced thrombocytopenia (HIT).
Discussion
The responses obtained from the Expert Round Table
Meeting and accompanying pre- and post-meeting sur-
veys have provided further insights into the use of
ECCO2R therapy across Europe. During a typical Delphi
process [24], 100% agreement is rare, and any consensus
is the result of multiple rounds of voting and discussion
that lead to a convergence of opinion. However, in areas
where clinical evidence is limited, as is the case for
ECCO2R therapy in patients with ARDS and ae-COPD,
using a modified Delphi method may offer insight into
the current practice of experienced users, which could
help inform decision making in local clinical practice.
Additionally, the use of the Delphi method to guide
these discussions and reach points of consensus will be
of potential benefit for the design of future trials. Specif-
ically, the discussions provide insight relevant to inclu-
sion criteria, guidance on the management of patients
while receiving ECCO2R therapy and possible primary
and secondary endpoints.
Key areas of consensus for the use of ECCO2R therapy
in the treatment of patients with ARDS or ae-COPD
were identified. There was consensus among the group
that the primary treatment goal of ECCO2R therapy for
patients with ARDS was to apply UPLV via managing
CO2 levels; this is in agreement with the findings of a
systematic literature review [30]. The group reached a
consensus that, when initiating ECCO2R therapy in pa-
tients with ARDS, driving pressure (≥ 14 cmH2O)
followed by Pplat (≥ 25 cmH2O) was the most important
criteria to consider. Higher PEEP, lower peak and plat-
eau pressures and lower respiratory rate have been
shown to correlate with improved survival in patients
with ARDS [7, 11, 31]. However, only the driving
Table 4 ECCO2R treatment initiation criteria for patients with
ae-COPD
Initiation criteria for patients at risk of NIV failure
Parameter
No decrease in PaCO2 while on NIV Consensus
No decrease in respiratory rate while on NIV Consensus
Clinical signs of respiratory failure Majority agreement
pH 7.25–7.30 Majority agreement
Baseline PaCO2 No agreement
Baseline respiratory rate No agreement
Initiation criteria for patients who are already intubated
- Patients who look like they will not be extubated early without
ECCO2R
○ Previous intubation for ae-COPD
○ Has failed a spontaneous breathing trial due to increased
dyspnoea
○ Reintubation after first extubation attempt despite NIV
○ Patients with severe bronchospasm who are difficult/impossible
to ventilate adequately or otherwise not responding to medical
treatment
○ Patients who remain hypercapnic and not improving with MV
- No hypoxemia preventing extubation
- MV < 72 h
- Patients with home NIV and good quality of life
Criteria for ECCO2R treatment considered to be of importance and selected
from the provided list. Target describes any potential target values identified.
Consensus means a consensus threshold (≥ 80%) was reached, majority
agreement means ≥ 50% agreed but consensus level was not reached, and no
agreement means < 50% agreed
Scoring and ranking was not conducted for this section during the meeting
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pressure was associated with increased mortality using a
multilevel mediation analysis in a large retrospective co-
hort study of patients with ARDS [32]. It is therefore
perhaps not surprising that the key treatment targets for
ECCO2R in ARDS identified by the group were reduc-
tions in driving pressure and respiratory rate.
A pH of < 7.25 was also considered by most of the
group to be a criterion for initiation of ECCO2R therapy
in this patient group. Indeed, a lower pH was recently
shown to be independently associated with ICU
mortality in the large prospective LUNG SAFE registry
[31]. Most of the group also agreed that ECCO2R should
be initiated at PaCO2 levels > 60–80mmHg. While it
was suggested that permissive hypercapnia provided
protection against lung injury in terms of lung perme-
ability, oxygenation and lung mechanics [33], more
recent data have shown a positive correlation between
hypercapnic acidosis and mortality [34, 35]. Raising pH
(> 7.30 or > 7.25) and decreasing PaCO2 levels were
considered important treatment targets, indicating that
there is a perception that ECCO2R is an important
therapy for the management of respiratory acidosis.
The experts were evenly split on the primary rationale
for ECCO2R therapy, either as a rescue therapy in
patients with ARDS undergoing injurious MV, or to
facilitate UPLV to prevent VILI. The results from the
post-meeting survey highlighted that the group agreed
that they would at least consider selecting ECCO2R as a
strategy in both settings. Ongoing (NCT02654327) [11]
randomised trials may help clarify the role of ECCO2R,
allowing UPLV in patients with acute hypoxemic
respiratory failure.
Table 5 ECCO2R treatment targets and weaning protocol for patients with ae-COPD
Treatment targets for patients with ae-COPD
Parameter Target Score
Comfortable patient – 27
pH > 7.35/7.30, no consensus on specific pH 23
Respiratory rate < 20–25 breaths/min 19
Decrease of PaCO2 by 10–20% – 18




Maintaining haemodynamic stability – 7
ECCO2R weaning protocol for patients with ae-COPD
1. Patient weaned from NIV for > 6 h
a. Excluding patients on home NIV or candidates for long-term NIV
2. Intubated patients weaned from MV for > 6 h
3. SpO2 ≥ 88% with supplemental O2 if needed
4. Reduce sweep gas flow rate by 1–3 L/min; check arterial blood gas after 1 h for:
a. pH ≥7.35 with respiratory rate < 25 breaths/min
b. PaO2 > 55mmHg
c. SpO2 > 88%
d. FiO2 < 40%
5. Repeat sweep gas reduction until zero gas flow reached, while arterial blood gas targets maintained
6. Remove ECCO2R after 6 h of stability of the aforementioned criteria
Treatment targets for ECCO2R considered to be of importance and selected from the provided list. Target describes any potential target values identified. Score
indicates the combined total score, with higher scores indicating a higher perceived importance. Consensus means a consensus threshold (≥ 80%) was reached,
majority agreement means ≥ 50% agreed but consensus level was not reached, and no agreement means < 50% agreed. The ECCO2R weaning protocol for
patients with ae-COPD was developed and voted on during the meeting, with all attendees in agreement
Table 6 Heparin anticoagulation strategy
1. Anticoagulation with intravenous unfractionated heparin, preferably
applied to the extracorporeal circuit
2. Monitor aPTT or anti-Xa or both
a. To obtain an aPTT of 1.5–2.0 times normal baseline (45–70 s), or
anti-Xa activity of 0.3–0.5 UI/mL
3. Initial bolus of heparin
a. 40–80 units/kg PBW
b. Bolus will not be performed in patients already on full
anticoagulation
c. Bolus routinely performed when guidewires have been inserted/or
after catheter insertion
4. Patients with proven HIT-2
a. Argatroban protocol, e.g. 0.5–2.0 μg/kg/min
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To the best of our knowledge, this is the first publica-
tion of a proposed weaning strategy for ECCO2R in pa-
tients with ARDS. The group reached a consensus
regarding a strategy for weaning patients from ECCO2R
in this setting. It was agreed that ECCO2R therapy
should be applied for at least 48 h in patients with
ARDS, and that a test for PaO2/FiO2 > 200mmHg while
maintaining a driving pressure < 14 cmH2O should be
carried out to determine weaning possibility. It was also
agreed that patients should be stable for a minimum of
12 h at the ventilation parameters outlined (see Table 3)
before any weaning attempt takes place [11].
In a randomised study exploring the role of helium/oxy-
gen in ae-COPD, the rate of patients failing on NIV and
requiring MV was 15% [36]. Identifying the subgroup of
patients with ae-COPD at high risk of NIV failure is in-
deed crucial to improve their outcomes by deploying ef-
fective preventive strategies. The panel identified ‘lack of
decrease in PaCO2’ and ‘respiratory rate during NIV’ as
important indicators of increased risk of NIV failure and
an indication for ECCO2R initiation. The group also felt
that it was important to allow enough time to show that
NIV was ineffective before initiating ECCO2R therapy.
Furthermore, there are numerous factors involved in NIV
failure, and the benefit of ECCO2R for this patient group
is still a matter of debate due to lack of data from rando-
mised clinical trials [15, 22].
For patients with ae-COPD who are already intubated,
the intended use of ECCO2R therapy is to rapidly allow
extubation, to facilitate oral nutrition and early physio-
therapy and to prevent muscle deconditioning [3].
Treatment targets identified by the group clearly fit in
with the strategy of reducing the duration of MV and
are in line with published data and wider views on the
use of ECCO2R therapy [1, 19]. The VENT-AVOID trial
(NCT03255057) is currently randomising patients to
further investigate the benefits of ECCO2R therapy in
patients at risk of NIV failure or who already have been
intubated after NIV failure.
Anticoagulation with intravenous unfractionated hep-
arin was the preferred strategy of the group. This reflects
recent studies in the literature in which unfractionated
heparin appears to be the anticoagulant most frequently
used in this setting [10, 11]. The post-meeting survey
highlighted that anticoagulant activity should be moni-
tored using activated partial thromboplastin time (aPTT)
and/or anti-Xa; the monitoring approach remains
dependent on local practice. For patients with proven
HIT, argatroban was the group’s preferred anticoagulant
[37, 38].
Limitations
The findings presented here relate to the experiences of
a relatively small number of physicians from centres
across Europe; evidence from a larger group of intensi-
vists from multiple regions of the world may be required
to support these observations. Certain topics were not
covered due to the scope of the meeting. Firstly, the
questions covered current practice and did not explore if
practices, e.g. inclusion policies of the respective centres,
had changed over time. Secondly, certain rarer indica-
tions, e.g. lung transplant, were not covered, as the
meeting focussed on the broader population of patients
requiring ECCO2R therapy, e.g. patients with ARDS or
ae-COPD. These questions could be covered as part of a
follow-up meeting. Additionally, while the authors took
every opportunity to ensure all relevant major articles
were cited, the purpose of the meeting was to under-
stand current practice as opposed to conducting a com-
prehensive literature analysis. Finally, the experiences
outlined are the physicians’ respective personal experi-
ences and are not a replacement for formal guidelines.
The reader should consider their patients’ needs and
local guidelines when performing ECCO2R therapy.
Conclusions
The insights from this group of experienced physicians
suggested that ECCO2R therapy may be a useful and ef-
fective supportive treatment for adults in the ICU with
both ARDS and ae-COPD. They have however
highlighted an urgent need for further evidence in the
form of randomised clinical trials and/or high-quality
prospective studies to help guide decision making. On-
going and published trials such as VENT-AVOID
(NCT03255057), REST (NCT02654327) [2] and SUPER-
NOVA (NCT02282657) [11, 12, 23] should provide the
data to support these guidelines.
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